A dual immunotherapy regimen of Opdivo (nivolumab) and Yervoy (ipilimumab) can prolong the survival of patients with untreated, inoperable malignant pleural mesothelioma (MPM), according to data from a Phase 3 clinical trial. Findings from this study about MPM, a severe form of cancer of the pleura (the protective lining surrounding the lungs), were presented by Bristol Myers Squibb, the therapies’ developer, at the 2020 World Conference on Lung Cancer Virtual Presidential Symposium. The event was hosted…
You must be logged in to read/download the full post.
The post Opdivo-Yervoy Combo Prolongs Survival of Patients With Inoperable Mesothelioma, Phase 3 Trial Shows appeared first on BioNewsFeeds.